Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.64 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 2/20 | 0.49 |
| ▸ | FNTB | P49356 | 2/20 | 0.49 |
| ▸ | DHFR | P00374 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575465 | 1.00 | CA2 (0.64) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL5438740 | 1.00 | CA2 (0.64) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL28881894 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL28881895 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387175 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387169 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| Water SCHEMBL4387164 | 0.99 | CA2 (0.62) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL10977896 | 0.89 | MAPT (0.54) | CA2CA1MAPTFOLH1CA12 | |
| SCHEMBL27508575 | 0.89 | CA2 (0.67) | CA2CA1MAPTNPC1TP53 | |
| SCHEMBL5699610 | 0.89 | CA2 (0.67) | CA2CA1MAPTNPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0809624-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | Bearsden Bio, Inc. (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025387-A1 | ALKYLCARBOXY AMINO ACIDS-MODULATORS OF THE KAINATE RECEPTOR | SYMPHONY PHARMACEUTICALS, INC. (US) | 1996-08-22 | — | — | WO | disclosed |
| US-5236927-A | Reduced toxicity; side effect reduction | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1993-08-17 | — | — | US | disclosed |
| EP-0204529-B1 | ANTI-CANCER QUINAZOLINE DERIVATIVES | BTG INTERNATIONAL LIMITED (GB) | 1993-03-31 | — | — | EP | disclosed |
| EP-0204529-A2 | Anti-cancer quinazoline derivatives | BTG INTERNATIONAL LIMITED (GB) | 1986-12-10 | — | — | EP | disclosed |
| US-4564616-A | Anti-cancer quinazoline derivatives | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1986-01-14 | — | — | US | disclosed |
| EP-0031237-B1 | QUINAZOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, COMPOSITIONS CONTAINING THEM AND THEIR USE AS ANTI-CANCER AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-10-17 | — | — | EP | disclosed |
| US-4447608-A | ANTITUMOR AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-05-08 | — | — | US | disclosed |
| EP-0031237-A1 | Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1981-07-01 | — | — | EP | disclosed |